Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
2024, Hepatoma Research
Hepatoma Research
Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection2019 •
Despite of the advances in clinical imaging and applied research in proteomic biomarkers, liver cancer, especially hepatocellular carcinoma remains detected at the very late and advanced stages when curable treatments are unavailable and ineffective. In this regard, there are still huge unmet medical needs in developing and clinically validating those high-potential protein biomarkers preferably in liquid biopsy samples. This review provides a glimpse of emerging biomarkers together with detection tools and techniques which are potentially commercially available to the markets. We also discuss several diagnostic biomarkers having therapeutic potential for developing first-in-class medicines.
Hepatoma Research
Molecular diagnosis and therapy of hepatocellular carcinoma: achievements and challenges2019 •
Hepatocellular carcinoma (HCC) is often associated with pre-existing chronic liver pathologies of different origin infections of hepatitis B virus (HBV) and hepatitis C virus. Clinically, the diagnosis and therapy for HCC are very important for the prognosis of patients. However, current methods for HCC diagnosis and therapy have no an optimal accuracy due to the tumor heterogeneity and the frequent late diagnosis. This review summarizes the new advances in molecular diagnosis and therapy of HCC, based on the recent novel biomarkers and new therapeutic strategies for HCC, including alpha-fetoprotein-L3, glypican-3, heat shock protein 90, dickkopf WNT signaling pathway inhibitor 1, paraoxonase 1, highly up-regulated in liver cancer. Moreover, epigenetic regulation, signal pathway, cellular and molecular targets for the immunotherapy, tumor microenviroment and genome sequencing analysis may serve as the molecular expression signatures in clinical practice. For promising new treatment strategy of HCC, targeting molecular therapy based on the restoration of tumor suppressor genes lost and inhibition of oncogenic genes is attractive. The new clinical trials for other molecular-targeted agents, including pembrolizumab, nivolumab, tivantinib, lenvatinib, cabozantinib, and ramucirumab, are ongoing in clinic. Interestingly, anti-HBV drugs display an amazing therapy for HBV-related HCC. In future, the global determination of more biomarkers may provide new insights into the diagnosis of HCC. More importantly, the diagnostic markers should be used to trace patient's follow-up disease progression, guiding doctors to judge and prescribe drugs for status of an illness, prognosis and other processes.
Anticancer Research
Alternative Biomarkers to Predict Tumor Biology in Hepatocellular CarcinomaARS Medica Tomitana
Diagnostic and Therapeutic Challenges in Hepatocellular Carcinoma2020 •
Introduction: Early detection of hepatocellular carcinoma is essential to provide effective therapy to high-risk patients, including patients with viral cirrhosis (eg HBV, HCV), haemochromatosis, alpha 1 antitrypsin deficiency or alcohol users. Material and method: The group of patients studied was represented by patients from the records of the Medical Clinic I of the Clinical Hospital “Saint Andrew the Apostle” Constanța for a period of 3 years (2017-2019). We included 82 patients aged between 32 and 82 years (60.22 ± 10.66 years) of which 55 were male and 27 were female. Results: Out of a total of 82 patients, 74 (90.25%) had cirrhosis (CH) and a number of 8 patients (9.75%) had chronic hepatitis without cirrhosis. Child-Pugh stage B had the highest prevalence among patients with hepatic cirrhosis. The etiological factor was hepatitis C virus infection 46 patients (56.1%), followed by hepatitis B virus infection 23 patients (28.05%), 4 patients (4.87%) had double hepatitis virus ...
2021 •
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Diagnostic, prognostic, and predictive biomarkers are urgently needed in order to improve patient survival. Indeed, the most widely used biomarkers, such as alpha-fetoprotein (AFP), have limited accuracy as both diagnostic and prognostic tests. Liver biopsy provides an insight on the biology of the tumor, but it is an invasive procedure, not routinely used, and not representative of the whole neoplasia due to the demonstrated intra-tumoral heterogeneity. In recent years, liquid biopsy, defined as the molecular analysis of cancer by-products, released by the tumor in the bloodstream, emerged as an appealing source of new biomarkers. Several studies focused on evaluating extracellular vesicles, circulating tumor cells, cell-free DNA and non-coding RNA as novel reliable biomarkers. In this review, we aimed to provide a comprehensive overview on the most relevant available evidence on novel ci...
Nature Communications
A high-throughput test enables specific detection of hepatocellular carcinomaHigh-throughput tests for early cancer detection can revolutionize public health and reduce cancer morbidity and mortality. Here we show a DNA methylation signature for hepatocellular carcinoma (HCC) detection in liquid biopsies, distinct from normal tissues and blood profiles. We developed a classifier using four CpG sites, validated in TCGA HCC data. A single F12 gene CpG site effectively differentiates HCC samples from other blood samples, normal tissues, and non-HCC tumors in TCGA and GEO data repositories. The markers were validated in a separate plasma sample dataset from HCC patients and controls. We designed a high-throughput assay using next-generation sequencing and multiplexing techniques, analyzing plasma samples from 554 clinical study participants, including HCC patients, non-HCC cancers, chronic hepatitis B, and healthy controls. HCC detection sensitivity was 84.5% at 95% specificity and 0.94 AUC. Implementing this assay for high-risk individuals could significantly d...
Journal of Personalized Medicine
Precision Medicine for Hepatocellular Carcinoma: Clinical PerspectiveHepatocellular carcinoma (HCC) is one of the major malignant diseases worldwide, characterized by growing incidence and high mortality rates despite apparent improvements in surveillance programs, diagnostic and treatment procedures, molecular therapies, and numerous research initiatives. Most HCCs occur in patients with liver cirrhosis, and the competing mortality risks from the tumor and the cirrhosis should be considered. Presently, previously identified risk factors, such as hepatitis virus infection, hepatic inflammation and fibrosis, and metabolic syndrome, may be used as chemoprevention targets. The application of precision medicine for HCC management challenges the one-size-fits-all concept; moreover, patients should no longer be treated entirely according to the histology of their tumor but based on molecular targets specific to their tumor biology. Next-generation sequencing emphasizes HCC molecular heterogeneity and aids our comprehension of possible vulnerabilities that ...
Hepatic Medicine: Evidence and Research
Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility2015 •
Hepatoma Research
Advances in early diagnosis of hepatocellular carcinoma2019 •
Hepatocellular carcinoma (HCC) is the most recurrent hepatic malignancy and the third in the cancer-related casualties in the west. The frequently-documented causes of HCC are chronic liver infections by hepatitis B virus or hepatitis C virus, nonalcoholic fatty liver disease, cirrhosis, exposure to aflatoxins and tobacco smocking, etc. Clinical presentation of this fatal disease ranges from asymptomatic to upper abdominal pain or common health conditions like weight loss or lethargy. Among current surveillance strategy for suspected patients, liver imaging and serum alpha fetoprotein estimation has been regularly recommended. However, sensitivity of this diagnostic methodology especially in early detections, often suffers from compromised sensitivity and selectivity. Various image based and serological biomarkers for HCC has been introduced in recent decades with varied sensitivity as stand-alone or combined diagnostic protocol. The current article will review the status of HCC diagnosis with respect to common diagnostic protocol, and upcoming novel biomarkers.
Journal of Clinical Medicine
Special Issue “The State of the Art in Endodontics”Currently, the term “modern endodontics” is used more often due to contemporary applied science and original materials that have been developed in recent years [...]
Список «Иудейской войны» Иосифа Флавия «руканискания» князя Дмитрия Васильевича Ромодановского // Обсерватория культуры. М., 2024. Т. 21. № 1. С. 61–75.
Список «Иудейской войны» Иосифа Флавия «руканискания» князя Дмитрия Васильевича РомодановскогоZbornik radova Vizantoloskog instituta
Obščestvo i izkustvo v B'lgarija prez XIII vek2009 •
71st Device Research Conference
Performance impact of post-regrowth channel etching on InGaAs MOSFETs having MOCVD source-drain regrowth2013 •
2008 •
JMIR Research Protocols
Prospective Associations Between Working Time Arrangements and Psychiatric Treatment in Denmark: Protocol for a Cohort Study2020 •
2011 •
Environmental Science & Technology
Haloacetic acid and Trihalomethane Formation from the Chlorination and Bromination of Aliphatic β-Dicarbonyl Acid Model Compounds2008 •
2023 •
Antimicrobial Agents and Chemotherapy
Evaluation of WLBU2 Peptide and 3- <i>O</i> -Octyl- <i>sn</i> -Glycerol Lipid as Active Ingredients for a Topical Microbicide Formulation Targeting <i>Chlamydia trachomatis</i>2010 •
Πολυμήχανος Man of Many Ways Papers in Honour of Professor Jan Driessen
‘The ties that bind’ Food consumption and the construction of corporate identities in Early Bronze Age Mesara2023 •
Journal of Quantitative Spectroscopy and Radiative Transfer
Consistent Franck-Condon Modeling of Geometry Changes for the S0→S1(ππ*) Excitation in Anthranilic Acid: LIF Spectroscopy Aided by CC2 or TDDFT Vibrations2019 •